

Item 8.01 Other Events.

On March 29, 2017, VistaGen Therapeutics, Inc. (the “Company”) announced that the European Patent Office has issued a Notice of Intention to Grant the Company's European Patent Application for AV-101, the Company's oral prodrug candidate in Phase 2 development for major depressive disorder. The granted claims covering multiple dosage forms of AV-101, treatment of depression and reduction of dyskinesias associated with L-DOPA treatment of Parkinson's disease will be in effect until at least January 2034. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Exhibits.

See Exhibit Index.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: March 29, 2017 By: /s/ Shawn K. Singh
Shawn K. Singh
Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
----------------	-------------

99.1	Press release issued by VistaGen Therapeutics Inc., dated March 29, 2017.
------	---